Obtained resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase

Obtained resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase domain mutations, specially the gatekeeper mutant T315I, is certainly a substantial problem for chronic myeloid leukemia (CML) patients. disease when portrayed in hematopoietic stem cells in mice (Daley et al., 1990). Motivated by Evofosfamide this, imatinib, a little molecule tyrosine kinase inhibitor (TKI) of… Continue reading Obtained resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase